Home > Publications database > Future Directions in Molecular Imaging of Neurodegenerative Disorders > print

001     916864
005     20230224084256.0
024 7 _ |a 10.2967/jnumed.121.263202
|2 doi
024 7 _ |a 0097-9058
|2 ISSN
024 7 _ |a 0022-3123
|2 ISSN
024 7 _ |a 0161-5505
|2 ISSN
024 7 _ |a 1535-5667
|2 ISSN
024 7 _ |a 2159-662X
|2 ISSN
024 7 _ |a 2128/33571
|2 Handle
024 7 _ |a 35649650
|2 pmid
024 7 _ |a WOS:000807305900010
|2 WOS
037 _ _ |a FZJ-2023-00156
082 _ _ |a 610
100 1 _ |a Barthel, Henryk
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Future Directions in Molecular Imaging of Neurodegenerative Disorders
260 _ _ |a New York, NY
|c 2022
|b Soc.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1673609495_26271
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The improvement of existing techniques and the development of new molecular imaging methods are an exciting and rapidly developing field in clinical care and research of neurodegenerative disorders. In the clinic, molecular imaging has the potential to improve early and differential diagnosis and to stratify and monitor therapy in these disorders. Meanwhile, in research, these techniques improve our understanding of the underlying pathophysiology and pathobiochemistry of these disorders and allow for drug testing. This article is an overview on our perspective on future developments in neurodegeneration tracers and the associated imaging technologies. For example, we predict that the current portfolio of β-amyloid and tau aggregate tracers will be improved and supplemented by tracers allowing imaging of other protein aggregation pathologies, such as α-synuclein and transactive response DNA binding protein 43 kDa. Future developments will likely also be observed in imaging neurotransmitter systems. This refers to both offering imaging to a broader population in cases involving the dopaminergic, cholinergic, and serotonergic systems and making possible the imaging of systems not yet explored, such as the glutamate and opioid systems. Tracers will be complemented by improved tracers of neuroinflammation and synaptic density. Technologywise, the use of hybrid PET/MRI, dedicated brain PET, and total-body PET scanners, as well as advanced image acquisition and processing protocols, will open doors toward broader and more efficient clinical use and novel research applications. Molecular imaging has the potential of becoming a standard and essential clinical and research tool to diagnose and study neurodegenerative disorders and to guide treatments. On that road, we will need to redefine the role of molecular imaging in relation to that of emerging blood-based biomarkers. Taken together, the unique features of molecular imaging-that is, the potential to provide direct noninvasive information on the presence, extent, localization, and quantity of molecular pathologic processes in the living body-together with the predicted novel tracer and imaging technology developments, provide optimism about a bright future for this approach to improved care and research on neurodegenerative disorders.
536 _ _ |a 5253 - Neuroimaging (POF4-525)
|0 G:(DE-HGF)POF4-5253
|c POF4-525
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Villemagne, Victor L.
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Drzezga, Alexander
|0 P:(DE-Juel1)177611
|b 2
|u fzj
773 _ _ |a 10.2967/jnumed.121.263202
|g Vol. 63, no. Supplement 1, p. 68S - 74S
|0 PERI:(DE-600)2040222-3
|n Supplement 1
|p 68S - 74S
|t Journal of nuclear medicine
|v 63
|y 2022
|x 0097-9058
856 4 _ |u https://juser.fz-juelich.de/record/916864/files/68S.full.pdf
|y OpenAccess
909 C O |o oai:juser.fz-juelich.de:916864
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 2
|6 P:(DE-Juel1)177611
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5253
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2022-11-19
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NUCL MED : 2021
|d 2022-11-19
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b J NUCL MED : 2021
|d 2022-11-19
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-19
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-19
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-2-20090406
|k INM-2
|l Molekulare Organisation des Gehirns
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-2-20090406
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21